glp 1 and binge eating disorder New hope for bulimia: GLP-1 drugs could be the key Navigating GLP-1 use in therapy

Description

The way that Ozempic interacts with other medications you are taking may also exacerbate the effects

doi: 10.1016/j.tim.2018.09.004 106 ScheenA

News provided by Novo Nordisk Jul 01, 2026, 07:00 ET Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events including death, heart attack, or stroke in adults with obesity and heart disease a claim only Wegovy can make Since launching in January 2026, Wegovy pill has reached 3 million prescriptions * Medicare GLP-1 Bridge participation now expands patient access to authentic, FDA-approved Wegovy , including the Wegovy pill PLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity

This holistic approach can enhance the effectiveness of the treatment and potentially provide better value for the investment

In addition, terminal sterilization, which is a regulatory requirement, presents further challenges because conventional methods such as autoclaving, gamma irradiation, or filtration may damage lipid structures or degrade peptide integrity